비교리스트

 카트 문의
시장보고서
상품코드
1530950

신장암 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Kidney Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 189 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신장암 진단 시장 - 조사 범위

TMR의 조사 보고서인 "신장암 진단 세계 시장"은 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지의 세계 신장암 진단 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 신장암 진단 시장의 연평균 성장률(CAGR %)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서 분석가들은 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 신장암 진단 시장을 추론했습니다.

시장 스냅샷
2023년 시장 규모 36억 달러
2034년 시장 규모 69억 달러
CAGR 6.2%

이 보고서는 세계 신장암 진단 시장의 경쟁 환경을 조사하고 있습니다. 세계 신장암 진단 시장에서 사업을 전개하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되어 있습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등은 이 보고서에서 소개하는 세계 신장암 진단 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 세계의 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

  • 파이프라인 분석
  • 주요 제품/브랜드 분석
  • 주요 M&A
  • COVID-19에 의한 산업에 대한 영향

제6장 세계의 시장 분석과 예측 : 제품 유형별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 제품 유형별, 2020-2034년
    • 플랫폼 기반 제품
    • 계측 기기 기반 제품
    • 키트와 시약
    • 기타(소모품 등)
  • 시장 매력 : 제품 유형별

제7장 세계의 시장 분석과 예측 : 검사 유형별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 검사 유형별, 2020-2034년
    • 생검
    • 영상 검사
    • 혈액 검사
    • 기타(유전자 검사 등)
  • 시장 매력 : 검사 유형별

제8장 세계의 시장 분석과 예측 : 암 스테이지별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 암 스테이지별, 2020-2034년
    • 스테이지 1
    • 스테이지 2
    • 스테이지 3
    • 스테이지 4
  • 시장 매력 : 암스테이지별

제9장 세계의 시장 분석과 예측 : 종양 유형별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 종양 유형별, 2020-2034년
    • 신세포암
    • 명세포암
    • 비명세포암
  • 시장 매력 : 종양 유형별

제10장 세계의 시장 분석과 예측 : 기술별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 기술별, 2020-2034년
    • FISH(Fluorescent In Situ Hybridization)
    • 차세대 시퀀싱
    • 형광면역측정법
    • CGH(Comparative Genomic Hybridization)
    • 기타(면역조직화학 등)
  • 시장 매력 : 기술별

제11장 세계의 시장 분석과 예측 : 최종사용자별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 최종사용자별, 2020-2034년
    • 병원
    • 암 연구 센터
    • 종양과 클리닉
    • 진단 센터
    • 외래 수술 센터
    • 기타(조사기관 등)
  • 시장 매력 : 최종사용자별

제12장 세계의 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별, 2020-2034년
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 : 지역별

제13장 북미의 시장 분석과 예측

제14장 유럽의 시장 분석과 예측

제15장 아시아태평양의 시장 분석과 예측

제16장 라틴아메리카의 시장 분석과 예측

제17장 중동 및 아프리카의 시장 분석과 예측

제18장 경쟁 상황

  • 시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
  • 시장 점유율 분석 : 기업별(2023)
  • 기업 개요
    • Siemens Healthineers
    • Koninklijke Philips N.V.
    • FUJIFILM Holdings Corporation
    • Grail
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific
    • Myriad Genetics, Inc.
    • Canon Medical Systems Corporation
    • QIAGEN N.V.
    • Illumina, Inc.
    • Ambry Genetics
    • Invitae Corp.
    • Centogene N.V.
ksm 24.08.28

Kidney Cancer Diagnostics Market - Scope of Report

TMR's report on the global kidney cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kidney cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kidney cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kidney cancer diagnostics market.

Market Snapshot
Market Value in 2023US$ 3.6 Bn
Market Value in 2034US$ 6.9 Bn
CAGR6.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kidney cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kidney cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kidney cancer diagnostics market.

The report delves into the competitive landscape of the global kidney cancer diagnostics market. Key players operating in the global kidney cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kidney cancer diagnostics market profiled in this report.

Key Questions Answered in Global kidney cancer diagnostics Market Report:

  • What is the sales/revenue generated by kidney cancer diagnostics across all regions during the forecast period?
  • What are the opportunities in the global kidney cancer diagnostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Kidney Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global kidney cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kidney cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kidney cancer diagnostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Kidney Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2020-2034
    • 6.3.1. Platform-based Products
    • 6.3.2. Instrument-based Products
    • 6.3.3. Kits and Reagents
    • 6.3.4. Others (Consumables, etc.)
  • 6.4. Market Attractiveness, by Product Type

7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Test Type, 2020-2034
    • 7.3.1. Biopsy
    • 7.3.2. Imaging Tests
    • 7.3.3. Blood Tests
    • 7.3.4. Others (Genetic Testing, etc.)
  • 7.4. Market Attractiveness, by Test Type

8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, By Cancer Stage, 2020-2034
    • 8.3.1. Stage 1
    • 8.3.2. Stage 2
    • 8.3.3. Stage 3
    • 8.3.4. Stage 4
  • 8.4. Market Attractiveness, By Cancer Stage

9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Tumor Type, 2020-2034
    • 9.3.1. Renal Cell Carcinoma
    • 9.3.2. Clear Cell Carcinoma
    • 9.3.3. Non-clear Cell Carcinoma
  • 9.4. Market Attractiveness, by Tumor Type

10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology

  • 10.1. Introduction and Definitions
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Tumor Type, 2020-2034
    • 10.3.1. Fluorescent In Situ Hybridization
    • 10.3.2. Next Generation Sequencing
    • 10.3.3. Fluoroimmunoassay
    • 10.3.4. Comparative Genomic Hybridization
    • 10.3.5. Others (Immunohistochemical, etc.)
  • 10.4. Market Attractiveness, by Tumor Type

11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user

  • 11.1. Introduction and Definitions
  • 11.2. Key Findings/Developments
  • 11.3. Market Value Forecast, by End-user, 2020-2034
    • 11.3.1. Hospitals
    • 11.3.2. Cancer Research Centers
    • 11.3.3. Oncology Clinics
    • 11.3.4. Diagnostic Centers
    • 11.3.5. Ambulatory Surgery Centers
    • 11.3.6. Others (Research Institutes, etc.)
  • 11.4. Market Attractiveness, by End-user

12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region, 2020-2034
    • 12.2.1. North America
    • 12.2.2. Europe
    • 12.2.3. Asia Pacific
    • 12.2.4. Latin America
    • 12.2.5. Middle East & Africa
  • 12.3. Market Attractiveness, by Region

13. North America Kidney Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product Type, 2020-2034
    • 13.2.1. Platform-based Products
    • 13.2.2. Instrument-based Products
    • 13.2.3. Kits and Reagents
    • 13.2.4. Others (Consumables, etc.)
  • 13.3. Market Attractiveness, by Product Type
  • 13.4. Market Value Forecast, by Test Type, 2020-2034
    • 13.4.1. Biopsy
    • 13.4.2. Imaging Tests
    • 13.4.3. Blood Tests
    • 13.4.4. Others (Genetic Testing, etc.)
  • 13.5. Market Attractiveness, by Test Type
  • 13.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 13.6.1. Stage 1
    • 13.6.2. Stage 2
    • 13.6.3. Stage 3
    • 13.6.4. Stage 4
  • 13.7. Market Attractiveness, By Cancer Stage
  • 13.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 13.8.1. Renal Cell Carcinoma
    • 13.8.2. Clear Cell Carcinoma
    • 13.8.3. Non-clear Cell Carcinoma
  • 13.9. Market Attractiveness, by Tumor Type
  • 13.10. Market Value Forecast, by Technology 2020-2034
    • 13.10.1. Fluorescent In Situ Hybridization
    • 13.10.2. Next Generation Sequencing
    • 13.10.3. Fluoroimmunoassay
    • 13.10.4. Comparative Genomic Hybridization
    • 13.10.5. Others (Immunohistochemical, etc.)
  • 13.11. Market Attractiveness, by Technology
  • 13.12. Market Value Forecast, by End-user, 2020-2034
    • 13.12.1. Hospitals
    • 13.12.2. Cancer Research Centers
    • 13.12.3. Oncology Clinics
    • 13.12.4. Diagnostic Centers
    • 13.12.5. Ambulatory Surgery Centers
    • 13.12.6. Others (Research Institutes, etc.)
  • 13.13. Market Attractiveness, by End-user
  • 13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.14.1. U.S.
    • 13.14.2. Canada
  • 13.15. Market Attractiveness Analysis
    • 13.15.1. By Product Type
    • 13.15.2. By Test Type
    • 13.15.3. By Cancer Stage
    • 13.15.4. By Tumor Type
    • 13.15.5. By End-user
    • 13.15.6. By Country

14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product Type, 2020-2034
    • 14.2.1. Platform-based Products
    • 14.2.2. Instrument-based Products
    • 14.2.3. Kits and Reagents
    • 14.2.4. Others (Consumables, etc.)
  • 14.3. Market Attractiveness, by Product Type
  • 14.4. Market Value Forecast, by Test Type, 2020-2034
    • 14.4.1. Biopsy
    • 14.4.2. Imaging Tests
    • 14.4.3. Blood Tests
    • 14.4.4. Others (Genetic Testing, etc.)
  • 14.5. Market Attractiveness, by Test Type
  • 14.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 14.6.1. Stage 1
    • 14.6.2. Stage 2
    • 14.6.3. Stage 3
    • 14.6.4. Stage 4
  • 14.7. Market Attractiveness, By Cancer Stage
  • 14.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 14.8.1. Renal Cell Carcinoma
    • 14.8.2. Clear Cell Carcinoma
    • 14.8.3. Non-clear Cell Carcinoma
  • 14.9. Market Attractiveness, by Tumor Type
  • 14.10. Market Value Forecast, by Technology, 2020-2034
    • 14.10.1. Fluorescent In Situ Hybridization
    • 14.10.2. Next Generation Sequencing
    • 14.10.3. Fluoroimmunoassay
    • 14.10.4. Comparative Genomic Hybridization
    • 14.10.5. Others (Immunohistochemical, etc.)
  • 14.11. Market Attractiveness, by Technology
  • 14.12. Market Value Forecast, by End-user, 2020-2034
    • 14.12.1. Hospitals
    • 14.12.2. Cancer Research Centers
    • 14.12.3. Oncology Clinics
    • 14.12.4. Diagnostic Centers
    • 14.12.5. Ambulatory Surgery Centers
    • 14.12.6. Others (Research Institutes, etc.)
  • 14.13. Market Attractiveness, by End-user
  • 14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.14.1. Germany
    • 14.14.2. U.K.
    • 14.14.3. France
    • 14.14.4. Italy
    • 14.14.5. Spain
    • 14.14.6. Rest of Europe
  • 14.15. Market Attractiveness Analysis
    • 14.15.1. By Product Type
    • 14.15.2. By Test Type
    • 14.15.3. By Cancer Stage
    • 14.15.4. By Tumor Type
    • 14.15.5. By End-user
    • 14.15.6. By Country/Sub-region

15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Product Type, 2020-2034
    • 15.2.1. Platform-based Products
    • 15.2.2. Instrument-based Products
    • 15.2.3. Kits and Reagents
    • 15.2.4. Others (Consumables, etc.)
  • 15.3. Market Attractiveness, by Product Type
  • 15.4. Market Value Forecast, by Test Type, 2020-2034
    • 15.4.1. Biopsy
    • 15.4.2. Imaging Tests
    • 15.4.3. Blood Tests
    • 15.4.4. Others (Genetic Testing, etc.)
  • 15.5. Market Attractiveness, by Test Type
  • 15.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 15.6.1. Stage 1
    • 15.6.2. Stage 2
    • 15.6.3. Stage 3
    • 15.6.4. Stage 4
  • 15.7. Market Attractiveness, By Cancer Stage
  • 15.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 15.8.1. Renal Cell Carcinoma
    • 15.8.2. Clear Cell Carcinoma
    • 15.8.3. Non-clear Cell Carcinoma
  • 15.9. Market Attractiveness, by Tumor Type
  • 15.10. Market Value Forecast, by Technology 2020-2034
    • 15.10.1. Fluorescent In Situ Hybridization
    • 15.10.2. Next Generation Sequencing
    • 15.10.3. Fluoroimmunoassay
    • 15.10.4. Comparative Genomic Hybridization
    • 15.10.5. Others (Immunohistochemical, etc.)
  • 15.11. Market Attractiveness, by Technology
  • 15.12. Market Value Forecast, by End-user, 2020-2034
    • 15.12.1. Hospitals
    • 15.12.2. Cancer Research Centers
    • 15.12.3. Oncology Clinics
    • 15.12.4. Diagnostic Centers
    • 15.12.5. Ambulatory Surgery Centers
    • 15.12.6. Others (Research Institutes, etc.)
  • 15.13. Market Attractiveness, by End-user
  • 15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.14.1. China
    • 15.14.2. Japan
    • 15.14.3. India
    • 15.14.4. Australia & New Zealand
    • 15.14.5. Rest of Asia Pacific
  • 15.15. Market Attractiveness Analysis
    • 15.15.1. By Product Type
    • 15.15.2. By Test Type
    • 15.15.3. By Cancer Stage
    • 15.15.4. By Tumor Type
    • 15.15.5. By End-user
    • 15.15.6. By Country/Sub-region

16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Product Type, 2020-2034
    • 16.2.1. Platform-based Products
    • 16.2.2. Instrument-based Products
    • 16.2.3. Kits and Reagents
    • 16.2.4. Others (Consumables, etc.)
  • 16.3. Market Attractiveness, by Product Type
  • 16.4. Market Value Forecast, by Test Type, 2020-2034
    • 16.4.1. Biopsy
    • 16.4.2. Imaging Tests
    • 16.4.3. Blood Tests
    • 16.4.4. Others (Genetic Testing, etc.)
  • 16.5. Market Attractiveness, by Test Type
  • 16.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 16.6.1. Stage 1
    • 16.6.2. Stage 2
    • 16.6.3. Stage 3
    • 16.6.4. Stage 4
  • 16.7. Market Attractiveness, By Cancer Stage
  • 16.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 16.8.1. Renal Cell Carcinoma
    • 16.8.2. Clear Cell Carcinoma
    • 16.8.3. Non-clear Cell Carcinoma
  • 16.9. Market Attractiveness, by Tumor Type
  • 16.10. Market Value Forecast, by Technology, 2020-2034
    • 16.10.1. Fluorescent In Situ Hybridization
    • 16.10.2. Next Generation Sequencing
    • 16.10.3. Fluoroimmunoassay
    • 16.10.4. Comparative Genomic Hybridization
    • 16.10.5. Others (Immunohistochemical, etc.)
  • 16.11. Market Attractiveness, by Technology
  • 16.12. Market Value Forecast, by End-user, 2020-2034
    • 16.12.1. Hospitals
    • 16.12.2. Cancer Research Centers
    • 16.12.3. Oncology Clinics
    • 16.12.4. Diagnostic Centers
    • 16.12.5. Ambulatory Surgery Centers
    • 16.12.6. Others (Research Institutes, etc.)
  • 16.13. Market Attractiveness, by End-user
  • 16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 16.14.1. Brazil
    • 16.14.2. Mexico
    • 16.14.3. Rest of Latin America
  • 16.15. Market Attractiveness Analysis
    • 16.15.1. By Product Type
    • 16.15.2. By Test Type
    • 16.15.3. By Cancer Stage
    • 16.15.4. By Tumor Type
    • 16.15.5. By End-user
    • 16.15.6. By Country/Sub-region

17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast

  • 17.1. Introduction
    • 17.1.1. Key Findings
  • 17.2. Market Value Forecast, by Product Type, 2020-2034
    • 17.2.1. Platform-based Products
    • 17.2.2. Instrument-based Products
    • 17.2.3. Kits and Reagents
    • 17.2.4. Others (Consumables, etc.)
  • 17.3. Market Attractiveness, by Product Type
  • 17.4. Market Value Forecast, by Test Type, 2020-2034
    • 17.4.1. Biopsy
    • 17.4.2. Imaging Tests
    • 17.4.3. Blood Tests
    • 17.4.4. Others (Genetic Testing, etc.)
  • 17.5. Market Attractiveness, by Test Type
  • 17.6. Market Value Forecast, By Cancer Stage, 2020-2034
    • 17.6.1. Stage 1
    • 17.6.2. Stage 2
    • 17.6.3. Stage 3
    • 17.6.4. Stage 4
  • 17.7. Market Attractiveness, By Cancer Stage
  • 17.8. Market Value Forecast, by Tumor Type, 2020-2034
    • 17.8.1. Renal Cell Carcinoma
    • 17.8.2. Clear Cell Carcinoma
    • 17.8.3. Non-clear Cell Carcinoma
  • 17.9. Market Attractiveness, by Tumor Type
  • 17.10. Market Value Forecast, by Technology, 2020-2034
    • 17.10.1. Fluorescent In Situ Hybridization
    • 17.10.2. Next Generation Sequencing
    • 17.10.3. Fluoroimmunoassay
    • 17.10.4. Comparative Genomic Hybridization
    • 17.10.5. Others (Immunohistochemical, etc.)
  • 17.11. Market Attractiveness, by Technology
  • 17.12. Market Value Forecast, by End-user, 2020-2034
    • 17.12.1. Hospitals
    • 17.12.2. Ambulatory Surgical Centers
    • 17.12.3. Nursing Centers
    • 17.12.4. Others (Long Term Care Centers, etc.)
  • 17.13. Market Attractiveness, by End-user
  • 17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 17.14.1. GCC Countries
    • 17.14.2. South Africa
    • 17.14.3. Rest of Middle East & Africa
  • 17.15. Market Attractiveness Analysis
    • 17.15.1. By Product Type
    • 17.15.2. By Test Type
    • 17.15.3. By Cancer Stage
    • 17.15.4. By Tumor Type
    • 17.15.5. By End-user
    • 17.15.6. By Country/Sub-region

18. Competition Landscape

  • 18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 18.2. Market Share Analysis, by Company (2023)
  • 18.3. Company Profiles
    • 18.3.1. Siemens Healthineers
      • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Financial Overview
      • 18.3.1.4. SWOT Analysis
      • 18.3.1.5. Strategic Overview
    • 18.3.2. Koninklijke Philips N.V.
      • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Financial Overview
      • 18.3.2.4. SWOT Analysis
      • 18.3.2.5. Strategic Overview
    • 18.3.3. FUJIFILM Holdings Corporation
      • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Financial Overview
      • 18.3.3.4. SWOT Analysis
      • 18.3.3.5. Strategic Overview
    • 18.3.4. Grail
      • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Financial Overview
      • 18.3.4.4. SWOT Analysis
      • 18.3.4.5. Strategic Overview
    • 18.3.5. Laboratory Corporation of America Holdings
      • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Financial Overview
      • 18.3.5.4. SWOT Analysis
    • 18.3.6. Thermo Fisher Scientific
      • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Financial Overview
      • 18.3.6.4. SWOT Analysis
      • 18.3.6.5. Strategic Overview
    • 18.3.7. Myriad Genetics, Inc.
      • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Financial Overview
      • 18.3.7.4. SWOT Analysis
      • 18.3.7.5. Strategic Overview
    • 18.3.8. Canon Medical Systems Corporation
      • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Financial Overview
      • 18.3.8.4. SWOT Analysis
      • 18.3.8.5. Strategic Overview
    • 18.3.9. QIAGEN N.V.
      • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Financial Overview
      • 18.3.9.4. SWOT Analysis
      • 18.3.9.5. Strategic Overview
    • 18.3.10. Illumina, Inc.
      • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Financial Overview
      • 18.3.10.4. SWOT Analysis
      • 18.3.10.5. Strategic Overview
    • 18.3.11. Ambry Genetics
      • 18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.11.2. Product Portfolio
      • 18.3.11.3. Financial Overview
      • 18.3.11.4. SWOT Analysis
      • 18.3.11.5. Strategic Overview
    • 18.3.12. Invitae Corp.
      • 18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.12.2. Product Portfolio
      • 18.3.12.3. Financial Overview
      • 18.3.12.4. SWOT Analysis
      • 18.3.12.5. Strategic Overview
    • 18.3.13. Centogene N.V.
      • 18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 18.3.13.2. Product Portfolio
      • 18.3.13.3. Financial Overview
      • 18.3.13.4. SWOT Analysis
      • 18.3.13.5. Strategic Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제